decline could be attributed to an increase of Baht 1,493 million or 16.36 percent in our impairment loss on loans and debt securities to cope with economic uncertainties. Operating profit before provision

Company Limited and its subsidiaries (“the Company”) would like to clarify herewith the operating result for the year 2018 as follows:- Financial Position As at 31 December 2018, total consolidated assets

. DOD2019/004 February 20, 2019 Subject: Management’s discussion and analysis of the Company’s operating results for the year 2018 period To: President The Stock Exchange of Thailand DOD Biotech Public

) August 9, 2017 Re : Report the operating result for the year ended June 30 ,2017 by more than 20 percent. To : Director and Manager the Stock Exchange of Thailand Approved by the Board of Directors of

consequently brought the decrease in net profit around 89.84 million baht or 17.49% comparing to last year. Financial Status As of June 30th, 2017, the Company had total assets at 4 ,631.76 million baht, rose by

DOD BIOTECH PUBLIC COMPANY LIMITED 111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000 Page 1 (Translate) NO. DOD 030/2019 August 13, 2019 Subject: Clarification of the operating

Company”) would like to announce the operating results for the 2Q 2018 and 1H 2018, which has been reviewed by an auditor as follows: For the 2Q 2018, the Company announces a consolidated net loss of

- Translation - Ref : LPH/SET 2018/016 August 10, 2018 Subject : Clarification on the Operating Results for the 3-month and 6-month period ended June 30, 2018 (Q2/2018) To : President The Stock

Company Limited and its subsidiaries (“the Company”) would like to announce the operating results for the three-month and nine-month periods ended September 30, 2018, which has been reviewed by an auditor

/2561 November 12, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q3/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited